加味逍遥散对功能性消化不良肝郁脾虚型患者胃电图及阿魏酸药动学特征的影响

Effect of Modified Xiaoyao Powder on Electrogastrographic Picture and Pharmacokinetic Characteristics of Ferulic Acid in Patients with Functional Dyspepsia of Gan-qi Stagnation with Pi-deficiency Syndrome Type

免费下载全文查看/发表评论下载PDF阅读器

DOI：

中文关键词: 加味逍遥散肝郁脾虚阿魏酸胃电图药物动力学

英文关键词:Modified Xiaoyao Powder Gan-qi stagnation with Pi-deficiency ferulic acid electrogastrogram pharmacokinetics

基金项目:国家杰出青年基金项目(No.30325045);国家自然科学基金资助项目(No.30271648);国家中医药管理局基础研究课题(No.02-03JP45)

作者	单位
任平	四川大学华西医院成都610041
黄熙	四川大学华西医院成都610041
李双庆	四川大学华西医院成都610041
许淑运	四川大学华西医院成都610041
万美华	四川大学华西医院成都610041
朱林	四川大学华西医院成都610041
唐文富	四川大学华西医院成都610041

摘要点击次数: 1759

全文下载次数: 2

中文摘要:

目的探讨加味逍遥散对功能性消化不良肝郁脾虚型患者在胃电图和药动学(PK)方面的作用机理。方法采用药效学与药动学同步测定方法。20例功能性消化不良肝郁脾虚证患者和21名健康自愿者口服自拟加味逍遥散,用胃肠分析仪和高效液相色谱同步观察药物作用前后肝郁脾虚证患者症状总积分、胃电图和阿魏酸(FA)体内PK特征的变化。结果(1)肝郁脾虚证患者症状总积分治疗后较治疗前下降(P<0·01)。(2)胃电图显示:肝郁脾虚证患者在胃体、胃小弯和胃大弯近窦部等检测点的平均峰值幅度、主频等值低于正常值,尤以餐后明显,且进餐后加重(P<0·01);经加味逍遥散治疗后,无论是餐前或餐后上述各值均有改善。(3)FA的PK参数变化:肝郁脾虚证患者的α、β和ka与健康对照组比较,各值均下降(P<0·05),加味逍遥散治疗后,与健康对照组比较,差异无显著性。结论加味逍遥散在改善肝郁脾虚型患者临床症状、胃电图观察指标的同时,对FA的PK参数也有明显影响。

英文摘要:

ObjectiveTo investigate the mechanism of Modified Xiaoyao Powder (MXP) on electrogastrogram (EGG) and pharmacokinetic characteristics of ferulic acid (FA) in patients with functional dyspepsia (FD) of Gan-qi stagnation with Pi-deficiency syndrome type (FD-GP). MethodsThe study was conducted following method of pharmacodynamics and pharmacokinetics synchronous determination. The 20 patients with FD-GP and 21 healthy volunteers enrolled were orally administrated with MXP to observe the changes in symptom scores, EGG and pharmacokinetic characteristics of FA in patients using gastrointestinal analyzer and high performance liquid chromatography (HPLC) before and after treatment. ResultsAfter treatment, the symptom scores of patients significantly decreased (P<0.01). EGG showed that the average amplitude of peak and dominant frequency, etc. at the monitoring points, including gastric body, lesser curvature and the near gastric antrum part of greater curvature, etc. were lower than the normal range, the changes were especially obvious and would be worsened after meals (P<0.01). After treatment by MXP, all the above indexes were improved either before or after meals. The pharmacokinetic parameters of FA in patients of FD-GP before treatment were lower than those in the healthy control group (P<0.05) and they were insignificant different by MXP comparing with those in the healthy control group. ConclusionMXP is effective not only in improving clinical symptoms and EGG, but also on pharmacokinetic parameters of FD-GP patients.

关闭